Ascendis Pharma A/S (ASND)
NASDAQ: ASND · IEX Real-Time Price · USD
135.21
-1.31 (-0.96%)
At close: Jul 19, 2024, 4:00 PM
135.26
+0.05 (0.04%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Ascendis Pharma Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Ascendis Pharma stock have an average target of 186.33, with a low estimate of 140 and a high estimate of 262. The average target predicts an increase of 37.81% from the current stock price of 135.21.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ASND stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 3 | 4 | 4 |
| Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Hold | 3 | 3 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 8 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Hold → Strong Buy Upgrades $156 → $175 | Hold → Strong Buy | Upgrades | $156 → $175 | +29.43% | Jun 25, 2024 |
| Stifel | Stifel | Strong Buy Initiates $200 | Strong Buy | Initiates | $200 | +47.92% | May 31, 2024 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $116 → $140 | Hold | Maintains | $116 → $140 | +3.54% | May 16, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $173 | Buy | Reiterates | $173 | +27.95% | May 15, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $260 → $262 | Buy | Maintains | $260 → $262 | +93.77% | May 3, 2024 |
Financial Forecast
Revenue This Year
447.92M
from 266.72M
Increased by 67.94%
Revenue Next Year
732.31M
from 447.92M
Increased by 63.49%
EPS This Year
-5.36
from -8.55
EPS Next Year
-1.17
from -5.36
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 532.4M | 1.0B | 1.9B | 2.9B | 3.7B |
| Avg | 447.9M | 732.3M | 1.2B | 1.9B | 2.5B |
| Low | 378.6M | 562.7M | 869.6M | 1.1B | 1.4B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 99.6% | 123.7% | 165.9% | 138.2% | 94.4% |
| Avg | 67.9% | 63.5% | 64.1% | 59.2% | 31.9% |
| Low | 41.9% | 25.6% | 18.7% | -5.8% | -27.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.77 | 2.03 | 8.46 | 27.78 | 38.25 |
| Avg | -5.36 | -1.17 | 3.23 | 15.67 | 23.22 |
| Low | -6.57 | -3.94 | 1.00 | 3.50 | 6.03 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 760.7% | 144.1% |
| Avg | - | - | - | 385.5% | 48.2% |
| Low | - | - | - | 8.3% | -61.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.